Amlitelimab is an investigational anti-OX40 ligand monoclonal antibody designed to normalize the overactive immune response in patients with atopic dermatitis.
Sanofi has reported mixed phase 3 data on amlitelimab, further muddying the prospec | Sanofi has reported mixed phase 3 data ...
Sanofi has announced that its amlitelimab has shown positive results in the treatment of patients 12 years and older with ...
Sanofi has said it will press ahead with regulatory filings for atopic dermatitis (AD) candidate amlitelimab after reporting ...
Sanofi (EPA: SASY) has announced encouraging late-stage clinical trial results for its investigational drug amlitelimab, ...
Sanofi's amlitelimab confirms its potential in atopic dermatitisIn the SHORE phase 3 study, amlitelimab in combination with topical therapies met ...
Shares of Corvus Pharmaceuticals rose after its investigational drug soquelitinib showed positive results in an early-stage trial in atopic dermatitis patients. The stock surged 50% to $12.10 in ...
A Bayesian network meta-analysis comparing four oral JAK inhibitors-upadacitinib, abrocitinib, baricitinib, and ivarmacitinib ...
Nearly 9 in 10 adults and parents of children with plaque psoriasis, atopic dermatitis, and seborrheic dermatitis being ...
How do early-life exposures shape the infant skin microbiome and atopic dermatitis risk? New cohort data reveal key ...
January 23, 2026 Following the positive COAST 1 results in September 2025, two additional global Phase III studies – SHORE and COAST 2 of amlitelimab, a fully human non-T cell depleting monoclonal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback